Piramal Pharma Releases Q3FY26 Earnings Call Transcript Following Results Discussion

1 min read     Updated on 29 Jan 2026, 09:45 AM
scanx
Reviewed by
Shriram SScanX News Team
Overview

Piramal Pharma has released the transcript of its Q3FY26 earnings conference call held on January 29, 2026, making it available on the company website as part of regulatory compliance under SEBI LODR regulations.

31205705

*this image is generated using AI for illustrative purposes only.

Piramal Pharma has announced the availability of its earnings call transcript for the quarter and nine months ended December 31, 2025, following the conference call held on January 29, 2026. The pharmaceutical company has made the transcript publicly accessible as part of its regulatory compliance obligations.

Regulatory Compliance Filing

The company filed the announcement with stock exchanges on January 30, 2026, in continuation of its earlier communication dated January 16, 2026. The filing was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Filing Details: Information
Conference Call Date: January 29, 2026
Results Period: Quarter and nine months ended December 31, 2025
Filing Date: January 30, 2026
Regulation: SEBI LODR Regulation 30(6)

Document Availability

The transcript of the conference call discussing the unaudited financial results (standalone and consolidated) has been made available on the company's official website at piramalpharma.com under the financial reports section. This follows the company's commitment to transparency and regulatory compliance in investor communications.

Exchange Communication

The announcement was formally communicated to both BSE Limited (scrip code: 543635) and National Stock Exchange of India Limited (symbol: PPLPHARMA). The filing was digitally signed by Company Secretary Tanya Sanish on January 30, 2026.

The availability of the earnings call transcript provides stakeholders with detailed insights into the company's Q3FY26 performance discussions and management commentary on the financial results for the reporting period.

Historical Stock Returns for Piramal Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+0.99%-2.19%+6.37%-16.44%-22.94%-13.20%

Piramal Pharma Limited Schedules Board Meeting for January 28, 2026 to Review Q3FY26 Financial Results

1 min read     Updated on 16 Jan 2026, 12:28 PM
scanx
Reviewed by
Ashish TScanX News Team
Overview

Piramal Pharma Limited has scheduled its board meeting for January 28, 2026, to consider Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025. The company notified BSE and NSE under Regulation 29 of SEBI Listing Regulations, with the trading window remaining closed from January 1 to January 30, 2026. Company Secretary Tanya Sanish signed the official communication on January 16, 2026.

30092325

*this image is generated using AI for illustrative purposes only.

Piramal Pharma Limited has officially notified stock exchanges about its upcoming board meeting scheduled for January 28, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company issued the intimation under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting will focus on considering and approving the unaudited financial results for both standalone and consolidated operations. The meeting covers the financial performance for the quarter and nine months ended December 31, 2025.

Meeting Parameter: Details
Date: Wednesday, January 28, 2026
Purpose: Q3FY26 Unaudited Financial Results
Coverage: Quarter and Nine Months Ended December 31, 2025
Format: Standalone and Consolidated Results

Trading Window Closure

In accordance with regulatory requirements, Piramal Pharma Limited has implemented a trading window closure for company securities. The trading window, which commenced closure on January 1, 2026, will remain closed until January 30, 2026, both days inclusive.

Trading Window Details: Information
Closure Start Date: Thursday, January 1, 2026
Closure End Date: Friday, January 30, 2026
Duration: Both days inclusive
Reason: Board meeting for financial results

Regulatory Compliance

The company has formally notified both major Indian stock exchanges about the scheduled board meeting. BSE Limited, where the company trades under scrip code 543635, and National Stock Exchange of India Limited, where it trades under the symbol PPLPHARMA, have been informed through official communication dated January 16, 2026.

Company Secretary Tanya Sanish signed the official intimation, ensuring compliance with SEBI Listing Regulations. The notification follows standard corporate governance practices for listed pharmaceutical companies in India, providing investors and stakeholders with advance notice of material financial disclosures.

Historical Stock Returns for Piramal Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+0.99%-2.19%+6.37%-16.44%-22.94%-13.20%

More News on Piramal Pharma

1 Year Returns:-22.94%